2026 MCI Breast Cancer Performance Improvement and Quality Improvement Series Evaluation Form - January 22, 2026

Please select one: *

I am in active clinical practice

I am retired

I am a student

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1	The information and/or skills learned will enhance my professional competence or ability. - 0
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 0

As a result of participating in this activity, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
Describe institutional strategies and workflows that support prevention and proactive management of toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, trastuzumab deruxtecan (T-DXd), and ado-trastuzumab emtansine (TDM-1)—including antiemetic protocols, diarrhea management algorithms, growth-factor use, oral care for stomatitis, dose-modification.	Describe institutional strategies and workflows that support prevention and proactive management of toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, trastuzumab deruxtecan (T-DXd), and ado-trastuzumab emtansine (TDM-1)—including antiemetic protocols, diarrhea management algorithms, growth-factor use, oral care for stomatitis, dose-modification. - 5	Describe institutional strategies and workflows that support prevention and proactive management of toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, trastuzumab deruxtecan (T-DXd), and ado-trastuzumab emtansine (TDM-1)—including antiemetic protocols, diarrhea management algorithms, growth-factor use, oral care for stomatitis, dose-modification. - 4	Describe institutional strategies and workflows that support prevention and proactive management of toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, trastuzumab deruxtecan (T-DXd), and ado-trastuzumab emtansine (TDM-1)—including antiemetic protocols, diarrhea management algorithms, growth-factor use, oral care for stomatitis, dose-modification. - 3	Describe institutional strategies and workflows that support prevention and proactive management of toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, trastuzumab deruxtecan (T-DXd), and ado-trastuzumab emtansine (TDM-1)—including antiemetic protocols, diarrhea management algorithms, growth-factor use, oral care for stomatitis, dose-modification. - 2	Describe institutional strategies and workflows that support prevention and proactive management of toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, trastuzumab deruxtecan (T-DXd), and ado-trastuzumab emtansine (TDM-1)—including antiemetic protocols, diarrhea management algorithms, growth-factor use, oral care for stomatitis, dose-modification. - 1	Describe institutional strategies and workflows that support prevention and proactive management of toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, trastuzumab deruxtecan (T-DXd), and ado-trastuzumab emtansine (TDM-1)—including antiemetic protocols, diarrhea management algorithms, growth-factor use, oral care for stomatitis, dose-modification. - 0
Summarize pharmacy-led safety initiatives, including creation and revision of powerplans, infusion-time optimization, prophylactic medication adjustments, and real-time integration of emerging toxicity data.	Summarize pharmacy-led safety initiatives, including creation and revision of powerplans, infusion-time optimization, prophylactic medication adjustments, and real-time integration of emerging toxicity data. - 5	Summarize pharmacy-led safety initiatives, including creation and revision of powerplans, infusion-time optimization, prophylactic medication adjustments, and real-time integration of emerging toxicity data. - 4	Summarize pharmacy-led safety initiatives, including creation and revision of powerplans, infusion-time optimization, prophylactic medication adjustments, and real-time integration of emerging toxicity data. - 3	Summarize pharmacy-led safety initiatives, including creation and revision of powerplans, infusion-time optimization, prophylactic medication adjustments, and real-time integration of emerging toxicity data. - 2	Summarize pharmacy-led safety initiatives, including creation and revision of powerplans, infusion-time optimization, prophylactic medication adjustments, and real-time integration of emerging toxicity data. - 1	Summarize pharmacy-led safety initiatives, including creation and revision of powerplans, infusion-time optimization, prophylactic medication adjustments, and real-time integration of emerging toxicity data. - 0
Discuss the role of interdisciplinary collaboration—pharmacy, oncology providers, nurse educators—in educating, patients, preventing complications, and coordinating care for ADC-related adverse events.	Discuss the role of interdisciplinary collaboration—pharmacy, oncology providers, nurse educators—in educating, patients, preventing complications, and coordinating care for ADC-related adverse events. - 5	Discuss the role of interdisciplinary collaboration—pharmacy, oncology providers, nurse educators—in educating, patients, preventing complications, and coordinating care for ADC-related adverse events. - 4	Discuss the role of interdisciplinary collaboration—pharmacy, oncology providers, nurse educators—in educating, patients, preventing complications, and coordinating care for ADC-related adverse events. - 3	Discuss the role of interdisciplinary collaboration—pharmacy, oncology providers, nurse educators—in educating, patients, preventing complications, and coordinating care for ADC-related adverse events. - 2	Discuss the role of interdisciplinary collaboration—pharmacy, oncology providers, nurse educators—in educating, patients, preventing complications, and coordinating care for ADC-related adverse events. - 1	Discuss the role of interdisciplinary collaboration—pharmacy, oncology providers, nurse educators—in educating, patients, preventing complications, and coordinating care for ADC-related adverse events. - 0

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

As a result of what was discussed at this activity what do you intend to do differently? Identify at least two learnings that could be incorporated into your practice *

What are the potential barriers or obstacles that might prevent you from implementing new strategies you learned at this activity? *

Comments

Name

You are here

2026 MCI Breast Cancer Performance Improvement and Quality Improvement Series Evaluation Form - January 22, 2026